Module 9 - Part 2 of 7

Biotechnology & Life Sciences

Navigate the complex intersection of patent law and life sciences. From the patentability of life forms to genetic resources protection, traditional knowledge safeguards, and the interface with biodiversity legislation - understand India's unique approach to biotech IP.

Duration: 90-120 minutes

8 Key Topics

10 Quiz Questions

Topic 1

Patentability of Life Forms

The patentability of living organisms represents one of the most contentious areas in intellectual property law, raising fundamental questions about the relationship between nature, invention, and property rights. The global debate began with a landmark US Supreme Court decision that opened the door to biotech patents.

Landmark Case: Diamond v. Chakrabarty (US Supreme Court, 1980)

Facts: Dr. Ananda Mohan Chakrabarty, a microbiologist working for General Electric, developed a genetically modified bacterium capable of breaking down crude oil, potentially useful for treating oil spills. He sought a patent for the bacterium itself.

Issue: Whether a live, human-made microorganism is patentable subject matter under 35 U.S.C. Section 101.

Held: In a 5-4 decision, the Supreme Court held that the bacterium was patentable. Chief Justice Burger wrote that the relevant distinction was not between living and inanimate things, but between products of nature and human-made inventions. The genetically modified bacterium was a "nonnaturally occurring manufacture or composition of matter - a product of human ingenuity."

Key Quote: "Congress intended statutory subject matter to include anything under the sun that is made by man."

Significance: This decision opened the floodgates for biotechnology patents globally and fundamentally changed the biotech industry's approach to IP.

International Positions

United States: Post-Chakrabarty, broad patentability including plants, animals, and genes (though Myriad limited gene patents)
Europe: EPC Article 53(b) excludes plant and animal varieties, but allows patents on biotechnological inventions with technical character
India: More restrictive approach under Section 3(j) - excludes plants, animals, and essentially biological processes
Brazil: Similar to India - excludes living organisms found in nature

Key Concept: Product of Nature vs. Human-Made

The fundamental distinction in biotech patentability is between products of nature (not patentable) and human-made inventions (potentially patentable). A naturally occurring organism, even if newly discovered, is not patentable. However, an organism that has been modified through human intervention to have characteristics not found in nature may be patentable - this is the "markedly different characteristics" test from Chakrabarty, later refined in Myriad.

The Myriad Refinement

The US Supreme Court in Association for Molecular Pathology v. Myriad Genetics (2013) clarified the limits of biotech patentability:

Naturally occurring DNA segments are products of nature: Even if isolated, they remain unpatentable
cDNA (complementary DNA) is patent-eligible: Because it is synthetically created and does not occur naturally
The boundary: Patents cannot claim discoveries of natural phenomena, but can claim applications of those discoveries

Topic 2

Section 3(j) - Plants, Animals, Seeds

India's approach to biotech patentability is distinctively restrictive, reflecting concerns about biodiversity, traditional knowledge, food security, and the rights of farmers. Section 3(j) of the Patents Act, 1970 is the key provision.

Section 3(j) - Patents Act, 1970

"The following are not inventions within the meaning of this Act:

(j) plants and animals in whole or any part thereof other than micro-organisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals"

Analysis of Section 3(j)

"Plants and animals in whole or any part thereof"

Excludes not just whole organisms but also parts - cells, tissues, organs, genes as they exist in organisms. This is broader than many other jurisdictions.

"Other than micro-organisms"

Micro-organisms are the exception - genetically modified micro-organisms (bacteria, fungi, algae, protozoa) may be patentable if they meet other patentability criteria.

"Including seeds, varieties and species"

Explicitly clarifies that seeds and plant varieties are excluded, even if modified. These are protected under the PPVFR Act instead.

"Essentially biological processes"

Processes that are primarily biological (crossing, selection) are excluded, even if some technical intervention exists. The test is whether the technical intervention is the essential determinant of the result.

What Remains Patentable?

Despite Section 3(j)'s restrictions, certain biotech innovations remain patentable in India:

Genetically modified micro-organisms: Bacteria, yeasts, fungi with novel characteristics
Processes for producing biotech products: Methods of genetic modification, fermentation processes
Isolated chemical compounds from biological sources: If meeting novelty and inventive step
Plasmids, vectors, recombinant DNA: Tools for genetic engineering
Biotechnological methods and applications: Non-biological processes using biological materials

Case Study: Monsanto Technology LLC v. Controller of Patents (Delhi High Court, 2018)

Facts: Monsanto's patent for Bt cotton technology (nucleic acid sequences encoding insecticidal proteins) was challenged. The patent covered the gene sequence and methods of producing transgenic plants.

Issue: Whether the patent claims fell within Section 3(j) exclusions.

Division Bench Held: Overturning the Single Judge, the Division Bench held that the nucleic acid sequences and methods were patentable. The Court distinguished between plants/seeds (excluded) and the underlying technology (potentially patentable). However, the scope of such patents vis-a-vis farmers' rights under other legislation remained a concern.

Significance: Clarified that biotechnological processes and genetic constructs may be patentable even if the resulting plants are not.

Topic 3

Section 3(i) - Essentially Biological Processes

Section 3(i) provides an additional exclusion for medical treatment methods, but the essentially biological processes exclusion in Section 3(j) deserves deeper analysis as it affects much of plant and animal biotechnology.

Section 3(i) - Patents Act, 1970

"(i) any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products"

Essentially Biological Processes - The Test

The key question is when a process involving biological material ceases to be "essentially biological" and becomes a technical/industrial process eligible for patent protection:

Key Concept: Technical Intervention Test

A process is "essentially biological" if the human technical intervention is not the determining factor in the result. Traditional breeding (crossing and selection) is essentially biological even if humans select parents and growing conditions. However, a process involving genetic engineering, where technical intervention fundamentally determines the outcome, is not essentially biological. The EPO applies a similar test - if the process consists entirely of natural phenomena like crossing and selection, it is essentially biological.

Examples of Classification

Essentially Biological (Not Patentable):
- Conventional plant breeding through crossing and selection
- Natural hybridization techniques
- Selection of plants with desired traits from natural variation
- Animal breeding through mating and selection
Not Essentially Biological (Potentially Patentable):
- Genetic transformation using recombinant DNA
- Gene editing using CRISPR-Cas9
- Mutagenesis through chemical or radiation treatment
- Cell fusion techniques beyond natural hybridization

Medical Treatment Exclusion

Section 3(i) excludes methods of treatment but allows patents on:

Pharmaceutical compositions for treatment
Medical devices and instruments
Diagnostic methods performed outside the body (in vitro)
Cosmetic treatments (not medical in nature)

Topic 4

Genetic Resources and Access (Nagoya Protocol)

Access to genetic resources for research and commercial development is governed by an international framework designed to ensure fair and equitable sharing of benefits arising from their utilization. The Nagoya Protocol is the key instrument.

The CBD Framework

The Convention on Biological Diversity (1992) established three objectives:

Conservation of biological diversity
Sustainable use of its components
Fair and equitable sharing of benefits from genetic resources

The CBD affirmed national sovereignty over genetic resources, requiring prior informed consent (PIC) and mutually agreed terms (MAT) for access.

Nagoya Protocol (2010)

The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization provides an operational framework implementing CBD's third objective. Key elements:

Access: Subject to PIC from the country providing resources
Benefit Sharing: On MAT between provider and user
Compliance: User countries must ensure their users comply with provider country requirements
Traditional Knowledge: TK associated with genetic resources requires community consent
Checkpoints: Countries must establish checkpoints to monitor compliance

India's Implementation

India implements the Nagoya Protocol through:

Biological Diversity Act, 2002: Primary legislation (predates Nagoya but aligned)
Biological Diversity Rules, 2004: Detailed procedures for access and benefit sharing
National Biodiversity Authority (NBA): Regulatory body for ABS compliance
State Biodiversity Boards: State-level implementation
Biodiversity Management Committees: Local-level documentation and management

Key Concept: Prior Informed Consent (PIC)

PIC requires that before accessing genetic resources, the user must obtain consent from the competent national authority (in India, the NBA for foreign entities). The consent process must provide full information about intended use, potential commercialization, and benefit-sharing arrangements. For resources associated with traditional knowledge, consent from relevant communities is also required. Failure to obtain PIC can invalidate IP rights based on those resources.

Topic 5

Traditional Knowledge Protection

Traditional knowledge (TK) encompasses the knowledge, innovations, and practices of indigenous and local communities developed over generations. Protecting TK from misappropriation while enabling its beneficial use is a major IP policy challenge.

The Biopiracy Problem

Biopiracy refers to the appropriation of genetic resources and traditional knowledge without authorization or fair compensation. Famous examples involving India include:

Case Study: The Turmeric Patent (USPTO, 1995-1997)

Facts: The University of Mississippi Medical Center obtained US Patent 5,401,504 for using turmeric in wound healing. The use of turmeric (haldi) for this purpose has been part of Indian traditional medicine for centuries.

Challenge: India's CSIR challenged the patent, providing evidence of prior art including ancient Sanskrit texts and papers in Indian medical journals documenting turmeric's wound-healing properties.

Outcome: The USPTO revoked the patent in 1997, finding it anticipated by prior art.

Significance: First successful challenge of a biopiracy patent; highlighted need for TK documentation and defensive protection mechanisms.

Neem Patent Cases

Multiple patents on neem-based products have been challenged:

EPO Patent EP0436257: W.R. Grace's patent on neem-based fungicide revoked in 2005 after 10-year opposition based on prior art showing traditional use
Multiple US Patents: Various patents on neem extracts and applications challenged based on traditional knowledge

India's TK Protection Mechanisms

Traditional Knowledge Digital Library (TKDL)

A database documenting traditional Indian knowledge from Ayurveda, Unani, Siddha, and Yoga in patent-compatible formats. Made available to major patent offices (USPTO, EPO, JPO, etc.) to serve as searchable prior art during patent examination.

Section 3(p) - Patents Act

"An invention which in effect, is traditional knowledge or which is an aggregation or duplication of known properties of traditionally known component or components" is not patentable.

Section 25(1)(k) - Pre-Grant Opposition

Allows opposition to patent grant if the invention is based on or derived from biological resources obtained without proper authorization under the Biodiversity Act.

Key Concept: Defensive vs. Positive Protection

Defensive Protection: Prevents others from obtaining wrongful IP rights over TK (e.g., TKDL, prior art documentation, Section 3(p)). Does not grant exclusive rights to communities but blocks misappropriation.

Positive Protection: Grants exclusive rights to TK holders enabling them to control use and benefit from commercialization. More difficult to implement due to TK's collective, intergenerational nature. Sui generis systems and geographical indications provide some positive protection.

Topic 6

Biodiversity Act 2002 Interface

The Biological Diversity Act, 2002 creates a comprehensive regulatory framework for access to biological resources and associated traditional knowledge, with direct implications for biotech patent applications.

Key Provisions of Biodiversity Act, 2002

Section 3: Foreign nationals/companies cannot access biological resources or TK without NBA approval
Section 4: Results of research cannot be transferred to foreigners without NBA approval
Section 6: Prior approval required for applying for IP rights (in or outside India) on inventions based on biological resources obtained from India
Section 7: Indian entities must give prior intimation to State Biodiversity Boards before obtaining biological resources for commercial use
Section 21: NBA to determine benefit-sharing arrangements

IP Application Requirements

Section 6(1) provides: "No person shall apply for any intellectual property right, by whatever name called, in or outside India for any invention based on any research or information on a biological resource obtained from India without obtaining the previous approval of the National Biodiversity Authority before making such application."

Consequences of Non-Compliance

For Patent Applications: Non-compliance with Section 6 can be ground for opposition and revocation under Section 25(1)(k) and 64(1)(p) of Patents Act
Criminal Penalties: Section 55 provides for imprisonment up to 5 years and fines up to Rs. 10 lakhs
Benefit Sharing Orders: NBA can impose benefit-sharing even retrospectively

Case Study: Divya Pharmacy Case (NBA Orders)

Facts: Divya Pharmacy (associated with Patanjali) obtained patents for formulations based on traditional knowledge and biological resources. NBA found non-compliance with Section 6 approval requirements.

NBA Action: Issued notices and directions for benefit-sharing arrangements. Companies must now seek approval before filing patent applications based on biological resources.

Significance: Demonstrated active enforcement of Biodiversity Act in IP context; companies must conduct due diligence on biological resource origins.

2023 Amendment Impact

The Biological Diversity (Amendment) Act, 2023 made significant changes:

Exempted codified traditional knowledge from benefit-sharing requirements
Simplified compliance for registered AYUSH practitioners
Decriminalized certain violations (made them civil offenses)
Raised concerns about weakening TK protection

Topic 7

Gene Patents and BRCA Controversy

The patentability of human genes has been one of the most controversial areas of biotechnology IP, raising questions about the commodification of the human body and access to diagnostic testing.

Landmark Case: Association for Molecular Pathology v. Myriad Genetics (US Supreme Court, 2013)

Facts: Myriad Genetics held patents on isolated BRCA1 and BRCA2 genes, mutations in which significantly increase breast and ovarian cancer risk. Myriad used these patents to maintain a monopoly on BRCA testing, charging over $3,000 per test with no competition.

Issue: Whether isolated human genes are patentable subject matter.

Held: Naturally occurring DNA segments are products of nature and not patent eligible merely because they have been isolated. However, cDNA (complementary DNA) is patent eligible because it is synthetically created.

Key Reasoning: "Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention."

Impact: Invalidated many gene patents; opened BRCA testing market to competition, dramatically reducing prices.

Indian Position on Gene Patents

India's approach is more restrictive than even post-Myriad US law:

Section 3(c): Discovery of any living thing or non-living substance occurring in nature is not patentable
Section 3(j): Plants and animals including parts thereof (which includes genes as they exist in organisms) are excluded
Combined Effect: Naturally occurring genes, whether isolated or not, are unlikely to be patentable in India
What May Be Patentable: Synthetically created DNA sequences, modified genes with novel functions, methods of gene modification

Key Concept: Gene Patents vs. Gene Applications

While patents on genes themselves face significant restrictions globally, patents on applications of gene knowledge remain available. This includes: diagnostic methods using gene sequences (in vitro), therapeutic applications, methods of genetic testing, gene therapy techniques, and genetically modified organisms (where permitted). The shift is from claiming genes as compositions to claiming methods and applications using genetic information.

Topic 8

Indian Biotech IP Cases

Several significant cases have shaped the landscape of biotechnology IP in India, providing guidance on how courts interpret the statutory exclusions and balance innovation incentives with public interest.

Case Study: Dimminaco A.G. v. Controller of Patents (Kolkata High Court, 2002)

Facts: Dimminaco sought to patent a process for preparing a vaccine for poultry containing live infectious bursitis virus. The Controller rejected the application on grounds that living organisms cannot be patented.

Issue: Whether a process involving living organisms is patentable.

Held: The Court held that while the product (the vaccine containing live virus) might face patentability issues, the process of preparing the vaccine was patentable. A process does not become unpatentable merely because a living organism is involved in it.

Significance: Established that process patents in biotechnology are available even when living organisms are involved, distinguishing process from product claims.

Nuziveedu Seeds v. Monsanto (2018-2019)

This complex dispute involved multiple issues:

Patent Validity: Whether Monsanto's Bt cotton technology patent was valid under Section 3(j)
Competition Issues: Whether Monsanto's licensing practices were anti-competitive
Trait Fee Regulation: Government's power to regulate technology fees

The Delhi High Court Division Bench held that while the underlying technology may be patentable, the plant variety produced was not, and raised questions about enforcing patents that result in plant varieties. The Supreme Court, in a limited ruling, restored Monsanto's right to enforce its patent pending further adjudication.

Practitioner Guidance: Biotech Patent Strategy in India

Focus patent claims on processes and methods rather than biological products
For micro-organisms, ensure clear demonstration of genetic modification and utility
Conduct thorough prior art search including TKDL for any TK-related innovations
Obtain NBA approval before filing patent applications involving Indian biological resources
Consider trade secret protection for innovations difficult to patent
Document compliance with Biodiversity Act requirements
Be aware that plant varieties should be protected under PPVFR Act, not Patents Act

Test Your Knowledge

Part 2 Quiz

Answer the following 10 questions to test your understanding of Biotechnology and Life Sciences IP.

Question 1 of 10

In Diamond v. Chakrabarty (1980), the US Supreme Court held that:

A) Living organisms can never be patented
B) Only naturally occurring organisms are patentable
C) Human-made living organisms with markedly different characteristics are patentable
D) Only dead matter is patentable subject matter

Explanation:

The Supreme Court held that a genetically modified bacterium was patentable because it was a "nonnaturally occurring manufacture or composition of matter - a product of human ingenuity." The key distinction is not between living and non-living, but between products of nature and human-made inventions with markedly different characteristics.

Question 2 of 10

Under Section 3(j) of the Indian Patents Act, which of the following is patentable?

A) A new plant variety
B) A genetically modified micro-organism
C) Seeds of a transgenic plant
D) A new animal breed

Explanation:

Section 3(j) excludes plants and animals in whole or any part thereof, including seeds, varieties, and species, but explicitly excludes micro-organisms from this exclusion. Therefore, genetically modified micro-organisms (bacteria, fungi, etc.) may be patentable if they meet other patentability criteria.

Question 3 of 10

The "essentially biological process" exclusion in Section 3(j) applies when:

A) The technical intervention is not the determining factor in the result
B) Any biological material is used
C) The process occurs in a laboratory
D) The process takes more than one year

Explanation:

A process is "essentially biological" if human technical intervention is not the determining factor - traditional breeding through crossing and selection is essentially biological. However, if technical intervention (like genetic engineering) fundamentally determines the outcome, the process is not essentially biological and may be patentable.

Question 4 of 10

Under the Nagoya Protocol, access to genetic resources requires:

A) Payment of a standard fee
B) Registration with WIPO
C) Publication in a scientific journal
D) Prior informed consent and mutually agreed terms

Explanation:

The Nagoya Protocol requires Prior Informed Consent (PIC) from the competent national authority of the provider country and Mutually Agreed Terms (MAT) for benefit sharing between provider and user. This ensures that genetic resources are accessed with proper authorization and that benefits are fairly shared.

Question 5 of 10

The Traditional Knowledge Digital Library (TKDL) serves as:

A) A patent registration system for traditional knowledge
B) A licensing platform for traditional remedies
C) A searchable prior art database for patent offices
D) A system for granting exclusive rights to communities

Explanation:

The TKDL documents traditional Indian knowledge from Ayurveda, Unani, Siddha, and Yoga in patent-compatible formats and makes it available to major patent offices as searchable prior art. This is a defensive protection mechanism - it prevents wrongful patents but does not grant exclusive rights to TK holders.

Question 6 of 10

Section 6 of the Biological Diversity Act, 2002 requires:

A) Payment of 10% royalty on all sales
B) NBA approval before applying for IP rights on inventions using Indian biological resources
C) Filing patent applications only in India first
D) Publishing details of biological resources used

Explanation:

Section 6(1) of the Biodiversity Act requires that no person shall apply for any IP right in or outside India for any invention based on research or information on biological resources obtained from India without obtaining previous approval from the National Biodiversity Authority. Non-compliance can be grounds for opposition and revocation.

Question 7 of 10

In Association for Molecular Pathology v. Myriad Genetics (2013), the US Supreme Court held that:

A) Isolated naturally occurring DNA is not patentable, but cDNA is patentable
B) All DNA sequences are patentable
C) No DNA can ever be patented
D) Only non-human DNA is patentable

Explanation:

The Court held that naturally occurring DNA segments are products of nature and not patent eligible merely because they have been isolated. However, cDNA (complementary DNA) is patent eligible because it is synthetically created - the lab technician creates something new when making cDNA.

Question 8 of 10

In the Turmeric Patent case, the USPTO revoked the patent because:

A) The invention was obvious
B) The applicant committed fraud
C) Living organisms cannot be patented
D) The claimed use was anticipated by traditional knowledge prior art

Explanation:

CSIR successfully challenged the turmeric patent by providing evidence of prior art - ancient Sanskrit texts and Indian medical journals documenting turmeric's use in wound healing for centuries. The patent lacked novelty because the claimed use was already known traditional knowledge, making this a landmark biopiracy case.

Question 9 of 10

In Dimminaco A.G. v. Controller of Patents, the Kolkata High Court held that:

A) Living organisms cannot be part of any patent
B) Vaccines are excluded from patentability
C) A process involving living organisms can be patentable
D) Only dead vaccines are patentable

Explanation:

The Court distinguished between product and process claims, holding that while the product (vaccine with live virus) might face patentability issues, the process of preparing the vaccine was patentable. A process does not become unpatentable merely because a living organism is involved in it.

Question 10 of 10

Section 3(p) of the Indian Patents Act excludes:

A) All pharmaceutical inventions
B) Inventions that are traditional knowledge or aggregation of known properties of traditionally known components
C) All biotechnology inventions
D) Inventions by foreign applicants

Explanation:

Section 3(p) excludes "an invention which in effect, is traditional knowledge or which is an aggregation or duplication of known properties of traditionally known component or components." This provision directly protects traditional knowledge from being patented by preventing claims that merely recite or aggregate known TK without any inventive contribution.